Efficacy and safety of monotherapy with sirukumab, an anti-IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis: results of a global, randomized, double-blind, parallel-group, phase 3 study (Arthritis and Rheumatology, 2016)

(untitled) - Taylor, P; Schiff, M; Wang, Q; Jiang, Y; Kurrasch, R; Daga, S; Rao, R; Hsu, B; Tak, P